{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"166-439-945-679-616","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"166-439-945-679-616","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":10826,"type":"PATENT","title":"KU Leuven - Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":7336,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8278,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately: univ* AND Leuven;
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 3165
Search Applicants and Owners separately: univ* AND Leuven;
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 3165
determining levels of FMR1 gene product in said tumor by analyzing a sample of the tumor,\n
thereafter assessing the tumor's metastatic potential based upon the determined levels of FMR1 gene product, and\n
altering therapy of the subject based upon the assessment of the tumor's metastatic potential."],"number":1,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, further comprising:\n
correlating increased levels of FMR1 gene product to an increased risk of metastasis."],"number":2,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the FMR1 gene product is Fmr1 mRNA."],"number":3,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the FMR1 gene product is FMRP protein."],"number":4,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the tumor is selected from the group consisting of breast cancer, colon cancer, and bladder cancer tumors."],"number":5,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 5, wherein the tumor is lymph node negative breast cancer tumor."],"number":6,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the levels are determined in vitro."],"number":7,"annotation":false,"claim":true,"title":false},{"lines":["A method of inhibiting metastasis of a tumor in a subject, the method comprising:\n
determining that the subject has a tumor, and\n
administering an FMR1 inhibitor to the subject\n
so as to inhibit metastasis of the tumor in the subject."],"number":8,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 8, wherein the FMR1 inhibitor is an inhibitor of Fmr1 mRNA."],"number":9,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 8, wherein the FMR1 inhibitor is an inhibitor of FMRP protein."],"number":10,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 8, wherein the tumor is breast cancer tumor."],"number":11,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 11, wherein the breast cancer tumor is lymph node negative breast cancer tumor."],"number":12,"annotation":false,"claim":true,"title":false},{"lines":["A pharmaceutical composition comprising an amount of an FMR1 inhibitor sufficient to inhibit FMR1 in a subject after being administered thereto."],"number":13,"annotation":false,"claim":true,"title":false},{"lines":["(canceled)"],"number":14,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 9, wherein the FMR1 inhibitor is an siRNA specific for Fmr1."],"number":15,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 10, wherein the FMR1 inhibitor is an anti-FMRP antibody."],"number":16,"annotation":false,"claim":true,"title":false},{"lines":["A method of treating a subject determined to have a tumor, the method comprising:\n
administering an amount of FMR1 inhibitor to the subject effective to inhibit metastasis of the tumor, and\n
monitoring the tumor for metastasis."],"number":17,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 8, wherein the FMR1 inhibitor is an siRNA specific for Fmr1 or an anti-FMRP antibody."],"number":18,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 18, wherein the tumor is a breast cancer tumor."],"number":19,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 19, wherein the breast cancer tumor is a lymph node negative breast cancer tumor."],"number":20,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 8, further comprising:\n
determining levels of FMR1 gene product in the tumor by analyzing a sample of the tumor,\n
thereafter assessing the tumor's metastatic potential based upon the determined levels of FMR1 gene product, and\n
altering therapy of the subject based upon the assessment of the tumor's metastatic potential."],"number":21,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}